RANDOMIZED CLINICAL-TRIAL OF 2 TREATMENT REGIMENS OF NATURAL SURFACTANT PREPARATIONS IN NEONATAL RESPIRATORY-DISTRESS-SYNDROME

被引:96
|
作者
SPEER, CP
GEFELLER, O
GRONECK, P
LAUFKOTTER, E
ROLL, C
HANSSLER, L
HARMS, K
HERTING, E
BOENISCH, H
WINDELER, J
ROBERTSON, B
机构
[1] UNIV GOTTINGEN, DEPT PAEDIAT, GOTTINGEN, GERMANY
[2] STADT KRANKENHAUS COLOGNE, DEPT MED STAT, COLOGNE, GERMANY
[3] STADT KRANKENHAUS COLOGNE, DEPT PAEDIAT, COLOGNE, GERMANY
[4] RUHR UNIV BOCHUM, DEPT PAEDIAT, BOCHUM, GERMANY
[5] UNIV ESSEN GESAMTHSCH, DEPT PAEDIAT, ESSEN, GERMANY
[6] STADT KRANKENHAUS BRAUNSCHWEIG, BRAUNSCHWEIG, GERMANY
[7] RUHR UNIV BOCHUM, DEPT MED INFORMAT & BIOMATH, BOCHUM, GERMANY
[8] KAROLINSKA INST, KAROLINSKA HOSP, RES UNIT EXPTL PERINATAL PATHOL, S-10401 STOCKHOLM, SWEDEN
关键词
SURFACTANT TREATMENT; RESPIRATORY DISTRESS SYNDROME; CUROSURF; SURVANTA;
D O I
10.1136/fn.72.1.F8
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Aims-To compare treatment regimens of two widely used natural surfactant preparations Curosurf and Survanta in respiratory distress syndrome (RDS). Methods-The effects of the two treatment regimens on gas exchange, ventilatory requirements, and 28 day outcome in infants with RDS were compared. Seventy fire preterm infants (birth weight 700-1500 g) with RDS requiring artificial ventilation with an FIO2 of greater than or equal to 0.4, were randomly selected at 1-24 hours of age. One group received an initial dose of Curosurf (200 mg/kg); the other group Survanta (100 mg/kg). Patients who remained dependent on artificial ventilation with an FIO2 of greater than or equal to 0.3 received up to two additional doses of Curosurf (each of 100 mg/kg) after 12 and 24 hours or up to three additional doses of Survanta (each of 100 mg/kg) between six and 48 hours after the initial dose. Results-There was a rapid improvement in oxygenation and ventilatory requirements were reduced in both groups. However, infants treated with Curosurf had a higher arterial:alveolar oxygen tension ratio and required a lower peak inspiratory pressure and mean airway pressure at several time points within 24 hours of randomisation (p<0.05-0.001). The incidences of pneumothorax in the Curosurf and Survanta groups were 6% and 12.5%, respectively; the corresponding figures for grades 3-4 intracerebral haemorrhage were 3% and 12.5%, respectively. Mortality was 3% in the Curosurf group and 12.5% in the Survanta group. However, these differences did not reach significance. Conclusion-The Curosurf treatment regimen resulted in a more rapid improvement in oxygenation than Survanta and reduced ventilatory requirements up to 24 hours aft er start of treatment. This was associated with a trend towards reduced incidence of serious pulmonary and nonpulmonary complications.
引用
收藏
页码:F8 / F13
页数:6
相关论文
共 50 条
  • [31] Randomized trial comparing two natural surfactants (Survanta vs. bLES) for treatment of neonatal respiratory distress syndrome
    Lam, BCC
    Ng, YK
    Wong, KY
    PEDIATRIC PULMONOLOGY, 2005, 39 (01) : 64 - 69
  • [32] Surfactant treatment of neonatal acute respiratory distress syndrome: Is "fortification" the answer?
    Chima, Ranjit S.
    Zingarelli, Basilia
    CRITICAL CARE MEDICINE, 2007, 35 (10) : 2442 - 2443
  • [33] Pulmonary surfactant combined with budesonide in the treatment of neonatal respiratory distress syndrome
    Guo, Hongxing
    Chen, Xinyang
    Hui, Haizhen
    Feng, Qingbo
    He, Yuanxiang
    TRANSLATIONAL PEDIATRICS, 2023, 12 (06) : 1288 - 1289
  • [34] USE OF SURFACTANT IN THE PREVENTION AND TREATMENT OF NEONATAL RESPIRATORY-DISTRESS SYNDROME
    REYNOLDS, MS
    WALLANDER, KA
    CLINICAL PHARMACY, 1989, 8 (08): : 559 - 576
  • [35] BACKGROUND TO NEONATAL RESPIRATORY-DISTRESS SYNDROME AND TREATMENT WITH EXOGENOUS SURFACTANT
    ROBERTSON, B
    DEVELOPMENTAL PHARMACOLOGY AND THERAPEUTICS, 1989, 13 (2-4): : 159 - 163
  • [36] Minimally Invasive Surfactant Administration for the Treatment of Neonatal Respiratory Distress Syndrome: A Multicenter Randomized Study in China
    Han, Tongyan
    Liu, Huiqiang
    Zhang, Hui
    Guo, Ming
    Zhang, Xuefeng
    Duan, Yang
    Sun, Fuqiang
    Liu, Xinjian
    Zhang, Xiang
    Zhang, Mingtao
    Liu, Fang
    Bao, Lisha
    Xiao, Min
    Liu, Weili
    Jiang, Rui
    Zheng, Jun
    Tian, Xiuying
    Gao, Qi
    Zhang, Wanxian
    Guo, Wei
    Li, Ling
    Tong, Xiaomei
    FRONTIERS IN PEDIATRICS, 2020, 8
  • [37] Implications of maternal vitamin D administration for the neonatal respiratory distress syndrome: A randomized clinical trial
    Boskabadi, H.
    Nakhaei, M. H. Ataee
    Maamouri, G. A.
    Saghafi, N.
    JOURNAL OF NEONATAL-PERINATAL MEDICINE, 2024, 17 (02) : 183 - 190
  • [38] STUDIES TO COMPARE TREATMENT REGIMENS - THE RANDOMIZED CLINICAL-TRIAL AND ALTERNATIVE STRATEGIES
    ELLENBERG, SS
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1981, 246 (21): : 2481 - 2482
  • [39] DUCTAL PATENCY IN NEONATES WITH RESPIRATORY-DISTRESS SYNDROME - A RANDOMIZED SURFACTANT TRIAL
    RELLER, MD
    BUFFKIN, DC
    COLASURDO, MA
    RICE, MJ
    MCDONALD, RW
    AMERICAN JOURNAL OF DISEASES OF CHILDREN, 1991, 145 (09): : 1017 - 1020